Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb (BMY) reported that its Opdivo plus Yervoy combination therapy showed sustained benefits over Pfizer's (PFE) Sutent in treating advanced kidney cancer after 8 years of follow-up in the Phase 3 CheckMate -214 trial. The combination therapy reduced the risk of death by 28% and showed improvements in overall survival, progression-free survival, overall response rate, and duration of response compared to Sutent. These results will be presented at the upcoming American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium. BMY shares saw a premarket increase of 0.52%.
January 23, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Opdivo plus Yervoy combination therapy shows significant long-term benefits in kidney cancer treatment, potentially strengthening the company's oncology portfolio.
The positive long-term results of the Opdivo plus Yervoy therapy in the Phase 3 trial are likely to reinforce investor confidence in BMY's oncology portfolio, potentially leading to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's Sutent was outperformed by Bristol Myers Squibb's combination therapy in a long-term kidney cancer study, which may impact the perception of Sutent's efficacy.
The news that Pfizer's Sutent was less effective than BMY's therapy over an 8-year period could negatively affect investor sentiment towards PFE's cancer drug, potentially leading to a short-term dip in stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80